Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 9, 1996

View Archived Issues

Pharmacia & Upjohn, McGill University claim antiparasitic MAb

Novel diagnostic agents for spongiform encephalopathies reported

New calcimimetic agents from ZymoGenetics

Bayer reveals sugar-modified cytostatic agents

New thrombin inhibitors under study at Merck & Co.

Novo Nordisk claims dopamine D3 receptor ligands for CNS indications

VIP analogs and derivatives claimed for smooth muscle relaxation

Therapeutically active NPY analog reported by academic source

Access in-licenses polymer platinum compounds

InSite Vision completes preliminary clinical trial of ophthalmic drug candidate

Dusa photodynamic therapy advances to phase III

Successful phase III results reported for British Biotech PAF antagonist

British Biotech discontinues development of MMP inhibitor

Another British Biotech compound reaches clinical stage

Medarex bispecific antibody enters phase II in colon cancer patients

MGI Pharma acquires drugs from Ilex Oncology

OsmoCyte approved for marketing in U.S.

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...